InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,894.47
(
1.93%
)
US TECH 100
20,047.17
(
1.82%
)
Dow Jones
43,559.76
(
3.17%
)
Brent Oil
75.26
(
-0.18%
)
Bitcoin
74,479.55
(
7.45%
)
Post# of 253536
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

exwannabe

Send PM Follow Ignore
Followers 89
Posts 18053
Boards Moderated 0
Alias Born 09/06/2006

exwannabe

Re: rkrw post# 72586

Monday, 02/02/2009 6:58:56 PM

Monday, February 02, 2009 6:58:56 PM

Post# of 253536
Re: Pg 36, Dyax, FDA AC's in general

"The application supports the efficacy of ecallantide ..."

Interesting, I honestly missed this on my first pass.

What puzzles me is the clear difference between the "Clinical Briefing Document" you are citing and the "Statistical Review and Evaluation" document located about 4/5ths down in the document that I was focused on.

I guess this makes it very likely to get a thumbs up by a vote of X-2, with the stat guy and some random person dissenting.

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up